Warning! GuruFocus detected
5 Severe warning signs
with I5X.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Precigen Inc
NAICS : 541714
SIC : 8731
ISIN : US46122T1025
Share Class Description:
FRA:I5X: Ordinary SharesDescription
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.8 | |||||
| Equity-to-Asset | 0.27 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -20.32 | |||||
| Beneish M-Score | -4.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.7 | |||||
| 3-Year EBITDA Growth Rate | -5.1 | |||||
| 3-Year EPS without NRI Growth Rate | 16.8 | |||||
| 3-Year FCF Growth Rate | 3.5 | |||||
| 3-Year Book Growth Rate | -36.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 337.35 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.95 | |||||
| 9-Day RSI | 23.33 | |||||
| 14-Day RSI | 31.97 | |||||
| 3-1 Month Momentum % | 48.86 | |||||
| 6-1 Month Momentum % | 82.2 | |||||
| 12-1 Month Momentum % | 17.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.76 | |||||
| Quick Ratio | 4.76 | |||||
| Cash Ratio | 4.55 | |||||
| Days Sales Outstanding | 68.63 | |||||
| Days Payable | 327.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.3 | |||||
| Shareholder Yield % | -7.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -8.71 | |||||
| Operating Margin % | -2412.87 | |||||
| Net Margin % | -3216.18 | |||||
| FCF Margin % | -1942.35 | |||||
| ROE % | -179.02 | |||||
| ROA % | -107.38 | |||||
| ROIC % | -130.86 | |||||
| 3-Year ROIIC % | 1.12 | |||||
| ROC (Joel Greenblatt) % | -712.46 | |||||
| ROCE % | -136.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 88.21 | |||||
| PB Ratio | 9.36 | |||||
| Price-to-Tangible-Book | 22.52 | |||||
| EV-to-EBIT | -2.11 | |||||
| EV-to-EBITDA | -2.19 | |||||
| EV-to-Revenue | 68.98 | |||||
| EV-to-Forward-Revenue | 148.62 | |||||
| EV-to-FCF | -3.53 | |||||
| Price-to-GF-Value | 6.26 | |||||
| Price-to-Median-PS-Value | 6.62 | |||||
| Earnings Yield (Greenblatt) % | -47.39 | |||||
| FCF Yield % | -21.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Precigen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.641 | ||
| EPS (TTM) (€) | -0.444 | ||
| Beta | 0.98 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 106.25 | ||
| 14-Day RSI | 31.97 | ||
| 14-Day ATR (€) | 0.085043 | ||
| 20-Day SMA (€) | 1.4836 | ||
| 12-1 Month Momentum % | 17.76 | ||
| 52-Week Range (€) | 0.6275 - 1.972 | ||
| Shares Outstanding (Mil) | 294.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Precigen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Precigen Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Precigen Inc Frequently Asked Questions
What is Precigen Inc(FRA:I5X)'s stock price today?
The current price of FRA:I5X is €1.13. The 52 week high of FRA:I5X is €1.97 and 52 week low is €0.63.
When is next earnings date of Precigen Inc(FRA:I5X)?
The next earnings date of Precigen Inc(FRA:I5X) is 2025-05-14 Est..
Does Precigen Inc(FRA:I5X) pay dividends? If so, how much?
Precigen Inc(FRA:I5X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers